USFDA USFDA warns Cipla for lapses in manufacturing practices at Pithampur facility Cipla, a prominent drug manufacturer, received a warning letter from the USFDA following concerns raised during a routine inspection at its Pithampur facility earlier this year. The letter, dated November 17, 2023.
News Cipla Introduces Ciplamed 2.0 For Healthcare Professionals Cipla has unveiled the next phase of its groundbreaking initiative with CiplaMed 2.0, dedicated to serving the needs of healthcare professionals. Building on the success of its predecessor, this upgraded platform offers an array of advanced resources and tools
